Asenapine, a new sublingual atypical antipsychotic

Journal of Pharmacology and Pharmacotherapeutics

Volumn 1, Issue 1, 2010, Pages 60-61

  Balaraman, R ^a   Gandhi, Hardik ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

BIPOLAR DISORDER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPESTHESIA; METABOLIC SYNDROME X; NONHUMAN; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84860265858     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.64538     Document Type: Short Survey

References (7)

1. Bennet PN, Brown MJ. Psychotropic drugs. In: Clinical Pharmacology. Edinburgh: Churchill Livingstone; 2008;367-412
2. Meltzer H. Antipsychotic agents and lithium. 10th ed. Basic and Clinical Pharmacology, In: Katzung BG, Masters SB, Trevor AJ, editors. New York: McGraw-Hill; 2009. p.487-507.
3. Meltzer HY, Dritselis A, Yasothan U, Kirkpatrick P. Asenapine. Nat Rev Drug Discov 2009;8:843-4.
4. Citrome L. Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84.
5. Schreing-Plough Croporation. Saphris (Asenapine) sublingual tablets. US prescribing information. Revised August 2009. Available from: http://www. spfiles.com/pisaphrisv1.pdf [Last accessed on 2009 Nov 30].
6. Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Neuropsychiatr Dis Treat 2009;5:483-90.
7. Frånberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilström B, et al. Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29. (Pubitemid 351200428)